PTC Therapeutics Inc (NAS:PTCT)
$ 44.225 -0.395 (-0.89%) Market Cap: 3.40 Bil Enterprise Value: 2.83 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 65/100

PTC Therapeutics Inc Call to Review Topline Results from Study 041 of Translarna™ (Ataluren) Transcript

Jun 21, 2022 / 12:00PM GMT
Release Date Price: $34.07 (+19.92%)
Operator

Good day, and thank you for standing by. Welcome to the Translarna (Ataluren) Study 041 Topline Results Call. (Operator Instructions). Please be advised that today's conference is being recorded. (Operator Instructions). I'd now like to hand the conference over to your speaker today, Kylie O'Keefe, SVP of Global Corporate and Commercial Strategy. Please go ahead.

Kylie O;Keefe
PTC Therapeutics, Inc. - SVP of Global Commercial & Corporate Strategy

' -

Good morning, everyone, and thank you for joining us today for the Study 041 Results Call. Joining me on today's call is our Chief Executive Officer, Dr. Stuart Peltz. Slides are available on the Investors section of the website for you to follow along during the presentation today.

I will now pass the call over to our Chief Executive Officer, Stuart Peltz. Stu?

Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director

Thanks, Kylie. And thank you all for joining us today. We're excited to share with you results of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot